<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869024</url>
  </required_header>
  <id_info>
    <org_study_id>1106M00401</org_study_id>
    <nct_id>NCT00869024</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy in Patients With Severe Heart Failure &amp; Undergoing Left Ventricular Assist Device Placement</brief_title>
  <acronym>ASSURANCE</acronym>
  <official_title>AsseSsment of Efficacy, Safety and Utility of intRa myocardiAl iNjection of Stem Cells in Patients With End Stage Heart Failure Undergoing LVAD Implantation (ASSURANCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the delivery of cells just after implantation of
      left ventricular assist device will help to improve the pumping function of your heart and
      minimize heart enlargement in the future.

      The cells will be obtained by aspiration or withdrawal of fluid from your bone marrow from
      your pelvic bone using a needle and syringe. This would not take place until 24-48 hours
      prior to your planned left ventricular assist device implantation. During the surgery the
      surgeons will inject the prepared cells that were taken from your bone marrow and inject it
      into your heart muscle.

      This study will test whether receiving your own bone marrow cells directly into your heart
      will help your heart to recover function after placement of a left ventricular assist device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who meet the inclusion and exclusion criteria and agree to participate will be
      enrolled in the study. All the patients will have a baseline EKG, Laboratory tests, 2D ECHO
      and PET/CT imaging.Day prior to the LVAD implantation all the patients will undergo bone
      marrow aspiration. Bone marrow aspirate will be processed according to the protocols used by
      that facility. After processing, the bone marrow mononuclear cells will then be suspended in
      2ml of 5% human serum albumin and labeled per the standard protocol of the facility.

      Patients will be randomized in a 2:1 fashion either to receive cells or 5% serum albumin.
      Under general anesthesia using the standard techniques the HeartMate II (LVAD) will be
      placed. The LVAD will be inserted into the LV apex (with removal of 2 x 2 cm ventricular
      core). The tissue core will be processed for RNA isolation and morphological analysis. CV
      surgeon will inject either the cells or placebo directly in to the myocardium in the LAD
      territory. Ten separate injections will be delivered into the LV free wall (20 X 106 cells /
      400 micro lit). The injection sites will be marked with Titanium surgical clips. Subjects
      will be managed at all times by the current standard of care in this hospital for the
      patients with an LVAD. Routine postoperative care procedures will be followed with close
      follow-up for dysrrhythmias or signs of infection.

      Tissue sample from the core of the left ventricular apex removed at the time of implantation
      of LVAD will be compared with the myocardium (marked with the surgical clips) from the
      explanted heart at the time of transplantation. These samples from the experimental subjects
      and control hearts will be examined for morphology for interstitial fibrosis, hypertrophy,
      myocyte diameter and myocytolysis as well as for gene expression using RT-PCR.

      Research-related follow-up will take place at weeks 2, 4, 6, 8 and months 6, 12, 18 and 24
      after LVAD implant at the Clinical Trial Center of the Cardiology Division at the University
      of Minnesota. Patients will be examined by the PI or Sub-I at each visit. Follow up data to
      be obtained at these clinic visits is outlined in the protocol
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2011</start_date>
  <completion_date type="Actual">March 29, 2016</completion_date>
  <primary_completion_date type="Actual">March 29, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Cell Delivery</measure>
    <time_frame>24 months</time_frame>
    <description>Safety as measured by the total number of adverse events per group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in Myocardial Viability by PET/CT Scan</measure>
    <time_frame>baseline, 10 weeks</time_frame>
    <description>Change in LAD segments from baseline to 10 weeks. PET scan viability is reported by segment on a scale of 0-4. A score of 0, 1, or 2 are categorized as viable/healthy heart tissue and a score of 3 or 4 are categorized as not viable/scar tissue. No change or better in viability will be reported to determine safety of cell injection. Measurement is reported as number of segment that remained the same or improved were considered &quot;safe&quot; for stem cell injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combined End Points of Death</measure>
    <time_frame>24 months</time_frame>
    <description>Number of participants who expired during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Turned Down Without Meeting LVAD Stopping Rules</measure>
    <time_frame>10 weeks</time_frame>
    <description>LVAD turn-down was completed at 10 weeks. Hemodynamic measurements were taken and reported with nominal LVAD support and then again at peak exercise. LVAD turn-down protocol was followed to ensure safety of patient while turning down their LVAD support. After each turn-down we waited 10 minutes and repeated ECHO, RHC, LVAD parameters, vital signs.
Stopping parameters for turn down:
Significant symptoms (clinician judgement, although low threshold to stop test)
CVP&gt;20 or increase by more than 10 (e.g., 5 to 16)
PCWP&gt;25 or increase by more than 10 (e.g., 11 to 22)
Hypotension
Increase in LVIDd by &gt;1.5 cm
Aortic valve opening minimally (less than 1 in 5 beats, e.g.)
The number of patients that could be turn-down without meeting stopping rules and were able to exercise were reported per group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Dimensions</measure>
    <time_frame>10 weeks</time_frame>
    <description>Change in left ventricular dimensions assessed by ECHO at baseline compared to 10 weeks with LVAD turn-down to 6000 RPMs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological Assessment</measure>
    <time_frame>24 months</time_frame>
    <description>Data collection was insufficient for data analysis. Samples were collected but no histological analysis performed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Stem Cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells</intervention_name>
    <description>Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Stem Cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe LV dysfunction with EF &lt; 30% with cardiomyopathy ( Ischemic and non ischemic)

          2. NYHA Class III and IV

          3. No revascularization options available

          4. LVAD placement as destination therapy or bridging to transplantation

          5. Age between 18-80 years

        Exclusion Criteria:

          1. History of recent malignancy( less than one year) .

          2. Unstable hemodynamics at the time of the implant; defined by need for increasing
             vasopressor medication in the last 24 hours or blood pressure &lt; 70 systolic, or
             cardiac index &lt; 1.3 liters/min.

          3. Coronary anatomy suitable for revascularization at the time of surgery

          4. Pregnancy confirmed by positive urine test

          5. Lactating mothers

          6. Renal failure with serum creatinine &gt;3.0, or are receiving chronic dialysis support.

          7. Inability to undergo PET/CT imaging.

          8. A history of any significant recent bleeding disorder or coagulation profile of
             concern for acute bleeding, such as INR &gt;2.0 (not on anticoagulant), platelet count
             &lt;100,000, or hemoglobin &lt;8.0 gr/dl.

          9. Patients with known infectious disease (Hepatitis, HIV) etc.

         10. Patients with three times or more of the upper limits of normal enzymes.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ganesh Raveendran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <results_first_submitted>January 15, 2020</results_first_submitted>
  <results_first_submitted_qc>February 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2020</results_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Left ventricular assist device</keyword>
  <keyword>Stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stem Cell Therapy</title>
          <description>Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="9">One patient intent to treat, did not receive study product</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stem Cell Therapy</title>
          <description>Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="8.68"/>
                    <measurement group_id="B2" value="65.1" spread="8.6"/>
                    <measurement group_id="B3" value="63.3" spread="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of Cell Delivery</title>
        <description>Safety as measured by the total number of adverse events per group.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Therapy</title>
            <description>Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Cell Delivery</title>
          <description>Safety as measured by the total number of adverse events per group.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Myocardial Viability by PET/CT Scan</title>
        <description>Change in LAD segments from baseline to 10 weeks. PET scan viability is reported by segment on a scale of 0-4. A score of 0, 1, or 2 are categorized as viable/healthy heart tissue and a score of 3 or 4 are categorized as not viable/scar tissue. No change or better in viability will be reported to determine safety of cell injection. Measurement is reported as number of segment that remained the same or improved were considered &quot;safe&quot; for stem cell injection.</description>
        <time_frame>baseline, 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Therapy</title>
            <description>Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Myocardial Viability by PET/CT Scan</title>
          <description>Change in LAD segments from baseline to 10 weeks. PET scan viability is reported by segment on a scale of 0-4. A score of 0, 1, or 2 are categorized as viable/healthy heart tissue and a score of 3 or 4 are categorized as not viable/scar tissue. No change or better in viability will be reported to determine safety of cell injection. Measurement is reported as number of segment that remained the same or improved were considered &quot;safe&quot; for stem cell injection.</description>
          <units>safe segments</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anterior wall base segment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior wall mid segment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior lateral wall base segment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior lateral wall mid segment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Combined End Points of Death</title>
        <description>Number of participants who expired during the study.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Therapy</title>
            <description>Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
          </group>
        </group_list>
        <measure>
          <title>Combined End Points of Death</title>
          <description>Number of participants who expired during the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Turned Down Without Meeting LVAD Stopping Rules</title>
        <description>LVAD turn-down was completed at 10 weeks. Hemodynamic measurements were taken and reported with nominal LVAD support and then again at peak exercise. LVAD turn-down protocol was followed to ensure safety of patient while turning down their LVAD support. After each turn-down we waited 10 minutes and repeated ECHO, RHC, LVAD parameters, vital signs.
Stopping parameters for turn down:
Significant symptoms (clinician judgement, although low threshold to stop test)
CVP&gt;20 or increase by more than 10 (e.g., 5 to 16)
PCWP&gt;25 or increase by more than 10 (e.g., 11 to 22)
Hypotension
Increase in LVIDd by &gt;1.5 cm
Aortic valve opening minimally (less than 1 in 5 beats, e.g.)
The number of patients that could be turn-down without meeting stopping rules and were able to exercise were reported per group.</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Therapy</title>
            <description>Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Turned Down Without Meeting LVAD Stopping Rules</title>
          <description>LVAD turn-down was completed at 10 weeks. Hemodynamic measurements were taken and reported with nominal LVAD support and then again at peak exercise. LVAD turn-down protocol was followed to ensure safety of patient while turning down their LVAD support. After each turn-down we waited 10 minutes and repeated ECHO, RHC, LVAD parameters, vital signs.
Stopping parameters for turn down:
Significant symptoms (clinician judgement, although low threshold to stop test)
CVP&gt;20 or increase by more than 10 (e.g., 5 to 16)
PCWP&gt;25 or increase by more than 10 (e.g., 11 to 22)
Hypotension
Increase in LVIDd by &gt;1.5 cm
Aortic valve opening minimally (less than 1 in 5 beats, e.g.)
The number of patients that could be turn-down without meeting stopping rules and were able to exercise were reported per group.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Dimensions</title>
        <description>Change in left ventricular dimensions assessed by ECHO at baseline compared to 10 weeks with LVAD turn-down to 6000 RPMs.</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Therapy</title>
            <description>Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Dimensions</title>
          <description>Change in left ventricular dimensions assessed by ECHO at baseline compared to 10 weeks with LVAD turn-down to 6000 RPMs.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to 10 weeks in LVEDD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="1.004"/>
                    <measurement group_id="O2" value="-0.57" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 10 weeks in LVESD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="1.07"/>
                    <measurement group_id="O2" value="-0.62" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histological Assessment</title>
        <description>Data collection was insufficient for data analysis. Samples were collected but no histological analysis performed.</description>
        <time_frame>24 months</time_frame>
        <population>Data collection was insufficient for data analysis. Samples were collected but no histological analysis performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Therapy</title>
            <description>Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
          </group>
        </group_list>
        <measure>
          <title>Histological Assessment</title>
          <description>Data collection was insufficient for data analysis. Samples were collected but no histological analysis performed.</description>
          <population>Data collection was insufficient for data analysis. Samples were collected but no histological analysis performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>Adverse events are classified as serious or non-serious. A serious adverse event is any AE that is:
fatal life-threatening requires or prolongs hospital stay results in persistent or significant disability or incapacity An important medical event</desc>
      <group_list>
        <group group_id="E1">
          <title>Stem Cell Therapy</title>
          <description>Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells: Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SNOWMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Increased bleeding</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Increased frequency of Atrial arrhythmias</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Increased frequency of Ventricular arrhythmias</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>New Liver Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Any infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Any Malignancies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>New Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ganesh Raveendran</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-626-4283</phone>
      <email>ravee001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

